Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.

ABSTRACT:

Background

Although the clinical efficacy of antimalarial artemisinin-based combination therapies in Africa remains high, the recent emergence of partial resistance to artemisinin in Plasmodium falciparum on the continent is troubling, given the lack of alternative treatments.

Methods

In this study, we used data from drug-efficacy studies conducted between 2016 and 2019 that evaluated 3-day courses of artemisinin-based combination therapy (artesunate-amodiaquine or artemether-lumefantrine) for uncomplicated malaria in Eritrea to estimate the percentage of patients with day-3 positivity (i.e., persistent P. falciparum parasitemia 3 days after the initiation of therapy). We also assayed parasites for mutations in Pfkelch13 as predictive markers of partial

SUBMITTER: Mihreteab S 

PROVIDER: S-EPMC10539021 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature